The best treatment for patients with advanced non-small cell lung cancer (NSCLC) and a poor performance status is not well defined. In this phase 2 trial, patients were randomized to receive treatment with either single-agent pemetrexed or 1 of 2 combination regimens. METHODS: Patients with newly diagnosed, histologically confirmed nonsquamous NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 were stratified by age and serum albumin level and were randomized (1:1:1) to 1 of 3 regimens: pemetrexed (arm 1), pemetrexed and bevacizumab (arm 2), or pemetrexed, carboplatin, and bevacizumab (arm 3). The response to treatment was assessed every 2 cycles; responding and stable patients continued treatment until progression or unacceptable toxicity. RESULTS: One hundred seventy-two patients were randomized, 162 patients began the study treatment, and 146 patients completed 2 cycles and were evaluated for their response. The median progression-free survival (PFS) was 2.8 months in arm 1, 4.0 months in arm 2, and 4.8 months in arm 3. The overall response rates were 15% in arm 1, 31% in arm 2, and 44% in arm 3. The overall survival was similar in the 3 treatment arms. All 3 regimens were relatively well tolerated. Patients receiving bevacizumab had an increased incidence of hypertension, proteinuria, and bleeding episodes, but most events were mild or moderate. CONCLUSIONS: All 3 regimens were feasible for patients with advanced NSCLC and an ECOG performance status of 2. The addition of bevacizumab to pemetrexed increased the overall response rate. The efficacy of pemetrexed/carboplatin/bevacizumab (median PFS, 4.8 months) approached the prespecified study PFS goal of 5 months. Larger studies will be necessary to define the role of bevacizumab in addition to standard pemetrexed and carboplatin in this population. Cancer 2018;124:1982-91.
INTRODUCTION
In recent years, treatments have improved for patients with stage IV non-small cell lung cancer (NSCLC). For patients with a good performance status, first-and second-line chemotherapy has improved survival, 1, 2 and targeted therapy has had a major impact on patients with specific activating mutations. [3] [4] [5] In addition, immunomodulatory agents targeting programmed death 1 or programmed death ligand 1 have recently been introduced and are in the process of being integrated into standard treatment. 6, 7 Despite these improvements, the optimal treatment for NSCLC patients with a poor performance status at diagnosis is not well defined. These patients are usually excluded from clinical trials of new agents, and many of the studies that have addressed this group have also included elderly patients, regardless of the performance status. 8, 9 The toxicity of traditional combination chemotherapy regimens is accentuated in these patients with a poor performance status, and treatment with single-agent chemotherapy has often been recommended. However, in a randomized Cancer and Leukemia Group B study (9730) comparing single-agent paclitaxel and a combination of paclitaxel and carboplatin, a subgroup of 99 patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 had improved survival when they were treated with the combination. 10 Further evaluation of treatments for patients with advanced NSCLC and a poor performance status remains necessary. The combination of pemetrexed and carboplatin is now a standard regimen for patients with advanced nonsquamous NSCLC, and it may have toxicity advantages in comparison with other platinum doublets. 11 The addition of bevacizumab to standard chemotherapy has improved survival for NSCLC patients with a good performance status, but it has not been evaluated in patients with a poor performance status because of concerns about toxicities such as arterial thromboembolic events. 12 This randomized phase 2 trial was designed to better define the roles of pemetrexed and bevacizumab in the first-line treatment of patients with advanced NSCLC and a poor performance status. Three regimens were evaluated: 1) single-agent pemetrexed; 2) pemetrexed and bevacizumab, and 3) pemetrexed, carboplatin, and bevacizumab. In the 3-drug regimen, carboplatin was administered at area under the concentration-time curve (AUC) 5 rather than AUC 6 to minimize myelosuppression.
MATERIALS AND METHODS
This randomized, open-label, phase 2 trial was initiated in June 2009 and was performed at 18 sites. The study was registered with ClinicalTrials.gov (NCT00892710). The study was conducted according to the ethical principles of the Declaration of Helsinki and was approved by the institutional review boards of each participating site before enrollment was commenced. All patients provided written informed consent.
Eligibility
Eligible patients were required to have histologically confirmed stage IV nonsquamous NSCLC. Tumors with a mixed histology containing squamous elements were eligible as long as the squamous component was not the dominant histology. Mixed tumors containing small cell anaplastic carcinoma were not eligible. All patients were required to have an ECOG performance status of 2 as assessed by their treating oncologist. Additional eligibility requirements included the following: measurable disease (according to version 1.1 of the Response Evaluation Criteria in Solid Tumors); adequate blood counts (absolute neutrophil count 1500/lL, hemoglobin level 10 g/ dL, and platelet count 100,000/lL); adequate organ function (bilirubin level < 1.5 3 institutional upper limit of normal [ULN], aspartate aminotransferase or alanine aminotransferase and alkaline phosphatase levels < 2.5 3 ULN or <5 3 ULN in patients with liver metastases, and calculated creatinine clearance > 45 mL/min); and the ability to take folic acid, vitamin B12, and dexamethasone in accordance with the study protocol.
Patients were excluded from this study if they had received any previous systemic therapy for stage IV NSCLC. Patients with brain metastases were eligible only if they had completed treatment for brain metastases more than 2 weeks before study entry. Several standard exclusion criteria related specifically to bevacizumab were included: proteinuria > 21 on a dipstick or > 1 g/24 h, serious nonhealing wounds or fractures, a history of hemoptysis or hematemesis, myocardial infarction or unstable angina within 6 months, uncontrolled hypertension, congestive heart failure (higher than grade 2), significant peripheral vascular disease, a history of stroke or transient ischemic attack within 6 months, any prior history of hypertensive crisis or hypertensive encephalopathy, and a history of fistula or gastrointestinal perforation within 6 months.
Pretreatment Evaluation
Before the initiation of treatment, all patients underwent a complete medical history and physical examination, a determination of their ECOG performance status, a review of their concomitant medications, complete blood counts, a chemistry profile, a calculation of their creatinine clearance, urinalysis, and a serum pregnancy test (for women of childbearing potential only). The baseline tumor status was assessed with computed tomography of the chest and abdomen and either a positron emission tomography scan or a bone scan. Scans to document measurable or evaluable disease were performed 4 weeks before the initiation of the study treatment.
Treatment
Before randomization, patients were stratified for the following clinical characteristics: age (<75 vs 75 years) and albumin (<3.5 vs 3.5 g/dL). Patients were then randomized (1:1:1) to 1 of 3 treatment arms (Fig. 1) . The treatment regimens were as follows: intravenous pemetrexed at 500 mg/m 2 (arm 1); intravenous pemetrexed (same dose) and intravenous bevacizumab at 15 mg/kg (arm 2); and intravenous pemetrexed (same dose), intravenous bevacizumab (same dose), and intravenous carboplatin at AUC 5 (arm 3). All regimens were administered in 21-day cycles. In arm 3, carboplatin was administered only during the first 4 cycles. Premedications for pemetrexed (folic acid, vitamin B12, and dexamethasone) and prophylactic antiemetics were administered according to standard guidelines. All regimens were continued until disease progression or unacceptable toxicity.
While this study was ongoing, a randomized phase 3 trial demonstrated the superiority of combination chemotherapy (paclitaxel and carboplatin) versus single-agent paclitaxel in the first-line treatment of patients with stage IV NSCLC and a poor performance status. 10 As a result, the accrual of patients to single-agent pemetrexed (arm 1) was stopped, and subsequent randomization (1:1) was continued to arms 2 and 3 only. 
Assessments
Patients were evaluated for their responses after the completion of 2 cycles (6 weeks) of the study treatment. Responses were assessed by the investigators and characterized according to version 1.1 of the Response Evaluation Criteria in Solid Tumors. 13 Patients with a complete response, a partial response, or stable disease continued treatment until disease progression or unacceptable toxicity occurred, with subsequent disease assessments at 6-week intervals.
Dose Modifications
Dose modifications were detailed in the study protocol and were based on the organ system exhibiting the worst toxicity. Dose modifications and management guidelines were outlined for hematologic toxicities and also for specific nonhematologic toxicities related to pemetrexed (diarrhea, mucositis, and liver function abnormalities) and bevacizumab (hypertension, hemorrhage, venous thrombosis, arterial thromboembolic event, fistula, congestive heart failure, proteinuria, gastrointestinal perforation, wound dehiscence, and reversible posterior leukoencephalopathy syndrome).
A maximum of 1 dose reduction of pemetrexed and carboplatin was allowed (dose level -1, pemetrexed at 400 mg/m 2 and carboplatin at AUC 4). No dose reductions of bevacizumab were allowed, but doses could be held to allow the resolution of toxicities deemed to be related to bevacizumab. If the dosing of pemetrexed or carboplatin was delayed because of toxicity, the dose of bevacizumab was also delayed. Patients who required dose delays of more than 21 days discontinued the protocol treatment. Patients who discontinued a component of the regimen because of toxicity or treatment intolerance were allowed to continue the protocol treatment with the remaining agents if they were judged to be benefiting from treatment. Granulocyte colony-stimulating factors were not used during the first treatment cycle but could be added during subsequent cycles in accordance with standard guidelines. The addition of granulocyte colonystimulating factors was not a substitute for protocolmandated dose reductions related to neutropenia.
Statistical Analysis
The goal of this randomized phase 2 study was to compare the efficacy of each of the 3 study regimens in the treatment of patients with stage IV NSCLC and a poor performance status against a historical control with nonparametric survival techniques. Progression-free survival (PFS) was the primary study endpoint; secondary endpoints included the time to progression, overall survival (OS), response rate, and toxicity. All survival endpoints were calculated with the intent-to-treat patient population (all patients randomized); response rates were calculated on the basis of the patients who received the study treatment.
When this study was initiated, treatment with either single-agent or combination chemotherapy was expected to produce a median PFS of approximately 3 months in this patient population. [8] [9] [10] To detect an increase in the median PFS from 3 to 5 months, under the assumption of a power of 80% and a 1-sided a level of .05, 54 evaluable patients per treatment arm were required. To account for a potential 20% unevaluable rate, the total target sample size was 183 randomized patients.
The primary endpoint, PFS, and the secondary survival endpoints were estimated with the Kaplan-Meier method.
14 The primary analysis was intended to estimate the efficacy of each treatment regimen with respect to the standard of care. Formal statistical comparisons of the treatment arms were not planned for survival endpoints; hazard ratios and 95% confidence intervals between the treatment arms were calculated. For response rates, the absolute and relative differences and the associated 95% confidence intervals were calculated. Response rates for the 3 regimens were compared with the chi-square method with Bonferroni correction.
Safety analyses were planned for all patients who received at least 1 dose of the study treatment. Adverse events and laboratory measurements were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 3.0). 15 An interim analysis to evaluate the safety of the 3 regimens was planned after 20 patients in each treatment arm had completed 2 cycles of therapy. If excessive treatment-related toxicities were seen in any of the treatment arms or if there were significant delays or dose adjustments required, an appropriate dose modification would be made or the arm would be closed to further accrual. The secondary objective was to assess the rate of response to each treatment at the first re-evaluation; in the case of insufficient activity, a treatment arm would be discontinued.
RESULTS

Patient Characteristics
Between June 2009 and November 2013, 172 patients were randomized (arm 1, 48; arm 2, 63; and arm 3, 61). The baseline patient characteristics were generally well balanced across the 3 treatment arms ( Table 1 ). The median age of the entire patient population was 72 years (range, 48-90 years). A large majority of the patients had stage IV NSCLC (93%) and were current or former cigarette smokers (94%).
Treatment Received
A summary of the treatment received by patients in each treatment arm is shown in Figure 1 . Of the 172 patients randomized, 162 received the study treatment, whereas 10 were randomized but withdrew before they received treatment. At the time of this writing, 161 patients had discontinued the study treatment; 117 of these patients (73%) had discontinued treatment because of tumor progression.
The median numbers of cycles received by patients in each of the 3 treatment arms were as follows: 3 cycles (range, 1-27) in arm 1, 4 cycles (range, 1-25) in arm 2, and 5 cycles (range, 1-21) in arm 3. Dose reductions were necessary for 10% of the patients in arm 1, 11% in arm 2, and 21% in arm 3. The percentages of the planned pemetrexed dose actually administered in arms 1, 2, and 3 were 98%, 99%, and 98%, respectively. Bevacizumab was discontinued in 8 patients (5%) because of toxicity or intolerance.
Interim Analysis
The planned interim analysis was performed after 20 patients in each treatment arm had completed 2 cycles of therapy. At that time, no unexpected safety concerns were found with any of the 3 treatment regimens. In addition, all 3 regimens demonstrated activity in this patient population (response rates: 13% in arm 1, 36% in arm 2, and 50% in arm 3). On the basis of this review, no changes in the study design were deemed necessary. However, because of emerging data demonstrating the superiority of pemetrexed and carboplatin in comparison with singleagent pemetrexed in this patient population, 16 accrual to arm A (single-agent pemetrexed) was discontinued.
Efficacy
The efficacy of each treatment regimen is detailed in Table 2 , and the estimated PFS curves for each treatment group are shown in Figure 2A . The median PFS times for (13) 6 (10) 4 (7) 16 (10) Abbreviation: CI, confidence interval.
arms 1, 2, and 3 were 2.8, 4, and 4.8 months, respectively. Patients treated in arm 3 (pemetrexed, carboplatin, and bevacizumab) had the longest PFS, although none of the treatments met the prespecified PFS study goal of 5 months. The probability of continuing PFS after 12 months was low for each regimen: 8%, 8%, and 18%, respectively. The estimated OS curves for each treatment regimen are shown in Figure 2B . The median survival times for arms 1, 2, and 3 were 7.7, 8.6, and 8.7 months, respectively. The probability of survival after 12 months was 30% for patients receiving pemetrexed alone, 32% for those receiving pemetrexed and bevacizumab, and 44% for those receiving pemetrexed, carboplatin, and bevacizumab.
Of the 162 patients who began the study treatment, 146 (90%) completed 2 cycles of the study treatment and were assessed for their response. The remaining 16 patients (10%) received fewer than 2 cycles of treatment and were considered unevaluable. The responses to each regimen are summarized in Table 2 . The overall response rates were 15% with pemetrexed, 31% with pemetrexed and bevacizumab, and 44% with pemetrexed, carboplatin, and bevacizumab. Patients receiving pemetrexed, carboplatin, and bevacizumab had a higher response rate than patients receiving single-agent pemetrexed (P 5 .004).
Toxicity
The toxicities observed in this study were consistent with the previously described toxicity profiles for each of these 3 regimens. Grade 3 and 4 toxicities are summarized and compared in Table 3 . As expected, myelosuppression was more common with the carboplatin-containing regimen (arm 3), although this regimen produced severe neutropenia and thrombocytopenia in only 15% and 18% of these patients, respectively, without resulting complications. Fatigue was the most common nonhematologic toxicity and occurred at similar frequencies in each of the treatment arms. Other grade 3 and 4 nonhematologic toxicities were relatively uncommon with all 3 regimens.
Toxicity attributable to bevacizumab is detailed in Table 4 . The incidence of bevacizumab-related adverse events was similar in the 2 bevacizumab-containing regimens (arms 2 and 3). Various bleeding episodes (most commonly epistaxis; 24%), hypertension (14%), and proteinuria (14%) were relatively common, but only 7 episodes were of grade 3 severity (hypertension, 5 patients; epistaxis, 1 patient; proteinuria, 1 patient). Two patients had serious arterial thromboembolic events (transient ischemic attack, 1 patient; cardiac ischemia, 1 patient).
DISCUSSION
A poor performance status is universally accepted as a negative prognostic feature in patients with advanced NSCLC. In addition, traditional chemotherapy combinations, particularly cisplatin-containing regimens, produce substantial toxicity in this patient population. As a result, patients with a poor performance status (an ECOG performance status of 2 or higher) have been routinely excluded from phase 3 clinical trials evaluating new treatments for lung cancer. Key advances in NSCLC treatment, including first-line treatment with pemetrexed and carboplatin, maintenance pemetrexed, and the addition of bevacizumab to chemotherapy, were all demonstrated in populations containing only patients with a good performance status.
Until recently, the standard treatment for NSCLC patients with a poor performance status was generally accepted to include single-agent chemotherapy (if any This result suggested that further evaluation of patients with an ECOG performance status of 2 was indicated. The randomized phase 2 trial reported here was designed to address 2 issues regarding the first-line treatment of NSCLC patients with a poor performance status. First, the issue of single-agent chemotherapy versus combination chemotherapy was addressed with pemetrexed and carboplatin, a chemotherapy doublet that is currently widely used and well tolerated. Second, the efficacy and toxicity of bevacizumab when added to single-agent or combination chemotherapy were assessed in this study.
Although this study was not designed to allow definitive comparisons between the 3 treatment arms, the longest median PFS and the highest 1-year PFS rate as well as the highest objective response rate were observed with the combination of pemetrexed, carboplatin, and bevacizumab. In this group, the median PFS (4.8 months) approached the pretreatment specified PFS goal of 5 months (vs 3 months for historical controls). Single-agent pemetrexed had the shortest median PFS (2.8 months) and the lowest objective response rate of the 3 regimens studied. OS was similar with all 3 regimens (7.7 months in arm 1, 8.6 months in arm 2, and 8.7 months in arm 3).
In comparing these groups, we found that patients receiving the combination regimen had longer PFS (4.8 vs 2.8 months; hazard ratio, 0.70), a higher PFS rate at 1 year (18% vs 9%), and a higher overall response rate (44% vs 15%; P 5 .004). The median was similar for the 2 treatments (8.7 vs 7.7 months). The addition of bevacizumab to pemetrexed (arm 2) also produced a numerically higher overall response rate in comparison with singleagent pemetrexed (31% vs 15%; P 5 .16), but other efficacy comparisons of these 2 regimens were similar. These findings are generally consistent with previous results from multiple first-line trials of NSCLC patients with a good performance status. In patients with a good performance status, combination chemotherapy has better efficacy than single-agent chemotherapy, [17] [18] [19] [20] and the addition of bevacizumab consistently improves the overall response rate and PFS with modest OS improvements in most studies. 12, 21, 22 The administration of all 3 regimens in this study was feasible, and none of the regimens produced unacceptable or unusual toxicity in this poor-performance status population. Patients who received bevacizumab as part of their therapy had hypertension, proteinuria, and various bleeding episodes more frequently, but the large majority of these events were mild to moderate in severity. Only 2 arterial thromboembolic events occurred that were considered possibly related to bevacizumab (transient ischemic attack, 1 patient; ischemic chest pain, 1 patient).
During the time our trial was being conducted, results were reported from an ECOG randomized phase 3 trial comparing single-agent pemetrexed with pemetrexed and carboplatin in patients with advanced NSCLC and an ECOG performance status of 2. 16 In this trial, improvements in the overall response rate, PFS, and OS were documented for patients receiving the combination chemotherapy regimen. Treatment-related toxicity was tolerable with both regimens. Although the study reported here is not powered to make definite conclusions regarding treatment efficacy, the outcomes for the ECOG trial's pemetrexed and carboplatin arm and arm 3 in our study (pemetrexed, carboplatin, and bevacizumab) are remarkably similar: 5.8 versus 4.8 months for PFS, 9.3 versus 8.7 months for OS, and 40% versus 44% for the 1-year survival rate.
In conclusion, our trial provides additional support for the superiority of combination chemotherapy versus single-agent chemotherapy in the treatment of patients with advanced NSCLC and an ECOG performance status of 2. In addition, our trial provides evidence that the addition of bevacizumab is also tolerable in this patient population; this includes the 3-drug cohort of pemetrexed, carboplatin, and bevacizumab. Bevacizumab-related toxicity was observed, but it was mild to moderate in most cases and did not appear to occur at a frequency greater than that in other NSCLC populations. Although the 3-drug regimen came close to meeting the prespecified PFS goal of 5 months, larger studies are necessary to assess its activity in this patient population in comparison with standard treatment with pemetrexed and carboplatin.
Although combination chemotherapy provides a modest benefit in this patient group, the overall prognosis remains poor with a median survival of less than 1 year. Further manipulation of chemotherapy regimens with or without bevacizumab seems unlikely to substantially improve current results. Future efforts should focus on the development and incorporation of novel treatments, including new targeted and immunomodulatory therapy.
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